Phase i study of s-1 plus fractional cisplatin as adjuvant chemotherapy for advanced gastric cancer in an outpatient setting (KOGC-03)

Tsunehiro Takahashi, Yoshiro Saikawa, Kazumasa Fukuda, Rieko Nakamura, Norihito Wada, Hirofumi Kawakubo, Hiroya Takeuchi, Hiromasa Takaishi, Yuukou Kitagawa

Research output: Contribution to journalArticle

Abstract

Aim: The aim of this phase I study was to adjust the dose of cisplatin as adjuvant combination chemotherapy with S-1 in an outpatient setting for gastric cancer.

Patients and Methods: The first course was initiated with S-1 monotherapy on days 1-28. From the second to the sixth course, S-1 was administered on days 1-28 and cisplatin was added on days 1, 15, and 29. The dose level of cisplatin was escalated as follows: 20 mg/m2 (level 1); 25 mg/m2 (level 2); 30 mg/m2 (level 3). Dose-limiting toxicity was a delay factor of the start of the next course due to incomplete recovery.

Results: The maximum tolerated and recommended doses were confirmed as level 3 and level 2, respectively.

Conclusion: Although further clinical trials are recommended to evaluate efficacy, this combination of S-1 plus cisplatin regimen is expected to become a standard adjuvant treatment for gastric cancer in the outpatient setting.

Original languageEnglish
Pages (from-to)467-472
Number of pages6
JournalAnticancer Research
Volume35
Issue number1
Publication statusPublished - 2015 Jan 1

Fingerprint

Adjuvant Chemotherapy
Cisplatin
Stomach Neoplasms
Outpatients
Maximum Tolerated Dose
Combination Drug Therapy
Clinical Trials
Therapeutics

Keywords

  • Adjuvant chemotherapy
  • Cisplatin
  • Gastric cancer
  • Outpatient setting
  • S-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase i study of s-1 plus fractional cisplatin as adjuvant chemotherapy for advanced gastric cancer in an outpatient setting (KOGC-03). / Takahashi, Tsunehiro; Saikawa, Yoshiro; Fukuda, Kazumasa; Nakamura, Rieko; Wada, Norihito; Kawakubo, Hirofumi; Takeuchi, Hiroya; Takaishi, Hiromasa; Kitagawa, Yuukou.

In: Anticancer Research, Vol. 35, No. 1, 01.01.2015, p. 467-472.

Research output: Contribution to journalArticle

@article{e8786f5c83604b9a9b802b08716ed279,
title = "Phase i study of s-1 plus fractional cisplatin as adjuvant chemotherapy for advanced gastric cancer in an outpatient setting (KOGC-03)",
abstract = "Aim: The aim of this phase I study was to adjust the dose of cisplatin as adjuvant combination chemotherapy with S-1 in an outpatient setting for gastric cancer.Patients and Methods: The first course was initiated with S-1 monotherapy on days 1-28. From the second to the sixth course, S-1 was administered on days 1-28 and cisplatin was added on days 1, 15, and 29. The dose level of cisplatin was escalated as follows: 20 mg/m2 (level 1); 25 mg/m2 (level 2); 30 mg/m2 (level 3). Dose-limiting toxicity was a delay factor of the start of the next course due to incomplete recovery.Results: The maximum tolerated and recommended doses were confirmed as level 3 and level 2, respectively.Conclusion: Although further clinical trials are recommended to evaluate efficacy, this combination of S-1 plus cisplatin regimen is expected to become a standard adjuvant treatment for gastric cancer in the outpatient setting.",
keywords = "Adjuvant chemotherapy, Cisplatin, Gastric cancer, Outpatient setting, S-1",
author = "Tsunehiro Takahashi and Yoshiro Saikawa and Kazumasa Fukuda and Rieko Nakamura and Norihito Wada and Hirofumi Kawakubo and Hiroya Takeuchi and Hiromasa Takaishi and Yuukou Kitagawa",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "35",
pages = "467--472",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Phase i study of s-1 plus fractional cisplatin as adjuvant chemotherapy for advanced gastric cancer in an outpatient setting (KOGC-03)

AU - Takahashi, Tsunehiro

AU - Saikawa, Yoshiro

AU - Fukuda, Kazumasa

AU - Nakamura, Rieko

AU - Wada, Norihito

AU - Kawakubo, Hirofumi

AU - Takeuchi, Hiroya

AU - Takaishi, Hiromasa

AU - Kitagawa, Yuukou

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Aim: The aim of this phase I study was to adjust the dose of cisplatin as adjuvant combination chemotherapy with S-1 in an outpatient setting for gastric cancer.Patients and Methods: The first course was initiated with S-1 monotherapy on days 1-28. From the second to the sixth course, S-1 was administered on days 1-28 and cisplatin was added on days 1, 15, and 29. The dose level of cisplatin was escalated as follows: 20 mg/m2 (level 1); 25 mg/m2 (level 2); 30 mg/m2 (level 3). Dose-limiting toxicity was a delay factor of the start of the next course due to incomplete recovery.Results: The maximum tolerated and recommended doses were confirmed as level 3 and level 2, respectively.Conclusion: Although further clinical trials are recommended to evaluate efficacy, this combination of S-1 plus cisplatin regimen is expected to become a standard adjuvant treatment for gastric cancer in the outpatient setting.

AB - Aim: The aim of this phase I study was to adjust the dose of cisplatin as adjuvant combination chemotherapy with S-1 in an outpatient setting for gastric cancer.Patients and Methods: The first course was initiated with S-1 monotherapy on days 1-28. From the second to the sixth course, S-1 was administered on days 1-28 and cisplatin was added on days 1, 15, and 29. The dose level of cisplatin was escalated as follows: 20 mg/m2 (level 1); 25 mg/m2 (level 2); 30 mg/m2 (level 3). Dose-limiting toxicity was a delay factor of the start of the next course due to incomplete recovery.Results: The maximum tolerated and recommended doses were confirmed as level 3 and level 2, respectively.Conclusion: Although further clinical trials are recommended to evaluate efficacy, this combination of S-1 plus cisplatin regimen is expected to become a standard adjuvant treatment for gastric cancer in the outpatient setting.

KW - Adjuvant chemotherapy

KW - Cisplatin

KW - Gastric cancer

KW - Outpatient setting

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=84920446752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920446752&partnerID=8YFLogxK

M3 - Article

C2 - 25550589

AN - SCOPUS:84920446752

VL - 35

SP - 467

EP - 472

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -